An International, Multicentre, Open-label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab After Neoadjuvant Chemotherapy Plus Durvalumab in Patients with Stage IIB-IIIB (N2) Resectable NSCLC ADOPT-LUNG is an international, multicentre, open-label randomised phase III tria...
(non-small cell lung cancer) that has not progressed beyond the chest, nor following concurrent platinum-based chemotherapy and radiation therapy.It is also indicated for use by individuals with specific types of bladder cancer, and is administered via an infusion.Individuals taking Imfinzi should ...
Patients who did not have disease progression after definitive concurrent chemoradiotherapy (CCRT) (chemotherapy: 2 cycles of platinum-based doublet chemotherapy, radiotherapy: 60 Gy/30 Fr) received durvalumab (10 mg/kg, every 2 weeks for up to 12 months) from the next day (allowed up to 5 ...
Chemotherapy can be a very important thing to add to the immune checkpoint inhibitors because it attacks the immune cycle of cancer. Therefore, we have several possibilities to increase the response rate, PFS, and OS. The PACIFIC trial is a very important trial because it covers a huge unmet ...
“The take-home is that we saw continued, maintained marked OS benefit when patients received adjuvant durvalumab following the completion of concurrent chemotherapy and radiation,” Piotrowska, a medical oncologist at Massachusetts General Hospital and an assistant professor at Harvard Medical School, sai...
I think [where] durvalumab is not an option, they do still have consolidative chemotherapy as a potential treatment option for patients.4 What is your approach toward pneumonitis diagnosis and treatment for patients receiving a single-agent checkpoint inhibitor? We don’t have any biomarkers ...
“Durvalumab and olaparib [given] concurrently with paclitaxel increased pCR rates in all 3 biomarker subsets where it was studied. The estimated probability that the experimental arm is superior to chemotherapy alone is greater than 98% in all subsets.” ...
Conclusions: Final analysis of the IMbrave151 study indicates a modest PFS benefit in intent- to-treat pts combining atezo with bev and chemotherapy. The trial is limited by small numbers and a non-comparative design. Exploratory analysis of correlative biomarkers suggests that high VEGF-A gene ...
Data on adjuvant chemotherapy alone for BTC are conflicting, and the SOC is treatment with capecitabine according to the UK BILCAP trial, even though BILCAP was formally negative. Based on the positive data for durvalumab in the TOPAZ-1 trial in BTC and for the STRIDE regimen in HCC ...
TNBC is difficult to treat and associated with high risk of recurrence despite standard systemic therapy (treatment targeting the entire body), which can include chemotherapy alone or in combination with immunotherapy (treatment targeting the immune system). To reduce the risk...